Reported value
$5.3B
2026 Q2 filing
| Ticker | Company | Weight | Shares | Change |
|---|---|---|---|---|
| RVMD | REVOLUTION MEDICINES INC | 22.31% | 6,361,323 | TRIMMED (-4.4%) |
| EWTX | Edgewise Therapeutics, Inc. | 7.77% | 10,215,455 | ADDED (+38.7%) |
| GMAB | GENMAB A/S | 6.76% | 13,133,131 | ADDED (+64.8%) |
| SYRE | SPYRE THERAPEUTICS INC | 6.38% | 3,840,778 | ADDED (+96.2%) |
| ORKA | Oruka Therapeutics, Inc. | 3.82% | 2,144,526 | TRIMMED (-7.6%) |
| TNGX | TANGO THERAPEUTICS INC | 3.72% | 6,357,523 | ADDED (+58.6%) |
| BLTE | BELITE BIO, INC | 3.55% | 1,232,877 | ADDED (+10.6%) |
| ERAS | ERASCA INC | 3.28% | 9,550,000 | TRIMMED (-8.1%) |
| TARS | TARSUS PHARMACEUTICALS INC | 3.27% | 2,775,649 | ADDED (+8.3%) |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | 2.71% | 480,000 | NEW |
| INSM | INSMED Inc | 2.65% | 1,325,977 | ADDED (+5.7%) |
| MBX | MBX BIOSCIENCES INC | 2.59% | 2,508,015 | NEW |
| PCVX | Vaxcyte, Inc. | 2.32% | 2,127,852 | TRIMMED (-55.6%) |
| VRDN | Viridian Therapeutics, Inc.\DE | 2.31% | 6,723,788 | ADDED (+113.5%) |
| OLMA | Olema Pharmaceuticals, Inc. | 2.03% | 8,670,576 | ADDED (+8.1%) |
| JBIO | JADE BIOSCIENCES INC | 1.19% | 2,857,405 | NEW |
| TYRA | TYRA BIOSCIENCES INC | 1.09% | 1,828,607 | TRIMMED (-11.0%) |
| ASMB | ASSEMBLY BIOSCIENCES INC | 0.80% | 1,553,748 | ADDED (+133.6%) |
| EYPT | EYEPOINT INC | 0.77% | 2,890,397 | TRIMMED (-8.0%) |
| ACHV | ACHIEVE LIFE SCIENCES INC | 0.61% | 4,951,856 | NEW |
| VOR | VOR BIOPHARMA INC | 0.60% | 1,750,000 | HELD |
| MPLT | MAPLIGHT THERAPEUTICS INC | 0.46% | 685,852 | NEW |
| KARD | KARDIGAN INC | 0.40% | 900,000 | NEW |
| LXEO | LEXEO THERAPEUTICS INC | 0.36% | 4,175,382 | TRIMMED (-32.5%) |
| EDIT | EDITAS MEDICINE INC | 0.34% | 5,586,625 | NEW |
| IVA | INVENTIVA SA - ADR | 0.28% | 4,000,000 | HELD |
The weights above sum to 82.4% of the fund’s reported 13F value. Only positions matched to a U.S.-listed ticker are listed; the remainder sits in unmatched or non-equity positions in the filing.
Exited this quarter: ABVX, BBOT, CYTK, GPCR, KLRS, MANE, MAZE, MIRM, ORIC, SRRK, URGN.
Source: SEC Form 13F filing for the quarter ended Jun 30, 2026, filed Aug 14, 2026. CIK 0001855655. Change labels compare with the fund’s previous quarterly filing. 13F filings cover long positions only.
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.